Adjuvant pembrolizumab approved by NICE
Late last week we learnt that the National Institute for [...]
Telaglenastat plus cabozantinib in patients with metastatic kidney cancer
Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]
ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer
Results from the phase 3 CLEAR studywere presented at the [...]
ESMO 2022: Atezolizumab as an adjuvant therapy
The results from the IMmotion010 study were presented at the [...]
ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer
In this phase 3 randomised study, presented at the European [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab
Neutrophils and eosinophils are white blood cells. In this study, [...]
Neoadjuvant axitinib may reduce venous tumour thrombus in kidney cancer
Neoadjuvant treatment is medication that is given before surgery to [...]
Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinoma
MiT family translocation renal cell carcinoma is a rare and [...]
Weight loss with cabozantinib use in patients with metastatic kidney cancer
This recent study looked at the effects of cabozantinib on [...]
